CliffBio
biologic

Beyfortus

nirsevimab-alip

Loss of exclusivityJuly 2035projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines US Inc.

Drug detail

Brand nameBeyfortus
Active ingredientnirsevimab-alip
Strength50MG/0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJuly 2023
Marketing statusRx

More from Sanofi Vaccines US Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Beyfortus patent cliff — loss of exclusivity July 2035 | CliffBio